Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoclonal antibodies | 5831 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Axatilimab-csfr is a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) expressed on monocytes and macrophages. Blocking CSF-1R with axatilimab-csfr reduces the levels of these circulating proinflammatory and profibrotic monocytes and monocyte-derived macrophage.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 14, 2024 | FDA | Incyte Corporation |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AG19 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Monoclonal antibodies |
| FDA MoA | N0000020036 | Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors |
| FDA EPC | N0000194108 | Colony Stimulating Factor-1 Receptor Blocker |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic graft-versus-host disease | indication | 402356004 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Macrophage colony-stimulating factor 1 receptor | Kinase | ANTIBODY BINDING | Kd | 11.24 | SCIENTIFIC LITERATURE | DRUG LABEL |
| ID | Source |
|---|---|
| CHEMBL4594608 | ChEMBL_ID |
| C000711669 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB16388 | DRUGBANK_ID |
| 4043711 | VANDF |
| 4043712 | VANDF |
| C5942943 | UMLSCUI |
| CHEBI:758080 | CHEBI |
| 2155851-88-8 | SECONDARY_CAS_RN |
| 388481 | MMSL |
| 43061 | MMSL |
| d10213 | MMSL |
| 13497 | IUPHAR_LIGAND_ID |
| 10953 | INN_ID |
| 2691526 | RXNORM |
| D11952 | KEGG_DRUG |
| R96Z451BMC | UNII |
| 019838 | NDDF |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-012 | INJECTION | 50 mg | INTRAVENOUS | BLA | 29 sections |
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-012 | INJECTION | 50 mg | INTRAVENOUS | BLA | 29 sections |
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-023 | INJECTION | 22 mg | INTRAVENOUS | BLA | 29 sections |
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-023 | INJECTION | 22 mg | INTRAVENOUS | BLA | 29 sections |
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-034 | INJECTION | 9 mg | INTRAVENOUS | BLA | 29 sections |
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-034 | INJECTION | 9 mg | INTRAVENOUS | BLA | 29 sections |
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-036 | INJECTION | 9 mg | INTRAVENOUS | BLA | 29 sections |
| NIKTIMVO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50881-047 | INJECTION | 22 mg | INTRAVENOUS | BLA | 29 sections |